https://www.selleckchem.com/products/b022.html
Among the patients, 74 (69%) were considered eligible for consolidation therapy with durvalumab. The overall response rate was 64%, and the two-year survival rate was 63%. Patients who received an ICI after relapse were associated with significantly better survival than those who did not receive an ICI (two-year survival rate 87% vs. 41%, respectively; P = 0.001). CONCLUSIONS Prior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA-NSCLC. The management of r
Curtir
Comentario
Compartilhar
